Basilea Pharmaceutica partners with Glioblastoma Foundation for glioblastoma drug candidate lisavanbulin.
Basilea Pharmaceutica partners with Glioblastoma Foundation to advance oncology drug candidate lisavanbulin for glioblastoma treatment. The drug candidate is being developed as a potential therapy for glioblastoma, the most common type of primary brain cancer. Basilea's Chief Medical Officer, Dr. Marc Engelhardt, emphasizes the importance of this partnership to provide patients with limited treatment options access to the drug candidate.
June 20, 2024
3 Articles